CompletedNCT05633953
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
Studying OBSOLETE: Cushing syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- RECORDATI GROUP
- Principal Investigator
- Mario M MALDONADO, MDRECORDATI GROUP
- Intervention
- Osilodrostat(drug)
- Enrollment
- 103 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2023
Study locations (1)
- Hôpital Haut-Lévèque, Pessac, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05633953 on ClinicalTrials.govOther trials for OBSOLETE: Cushing syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07296484Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)Sparrow Pharmaceuticals
- RECRUITINGNCT07156370Salivary Cortisol and Hypercortisolism in Type 2 DiabetesShanghai 6th People's Hospital
- RECRUITINGPHASE1, PHASE2NCT07350707Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's SyndromePeking Union Medical College Hospital
- ACTIVE NOT RECRUITINGNANCT05315388Effects of "Vitamin N" Nature Immersion Therapy on Stress Levels in Health Care Workers in the City of BogotáJeadran N. Malagón-Rojas
- ACTIVE NOT RECRUITINGNCT05382156Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's SyndromeRECORDATI GROUP
- RECRUITINGNANCT05368090Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary AldosteronismHaukeland University Hospital